Validating a targeted NGS approach for molecular characterization of gliomas
sponsored by QIAGEN
Targeted NGS has been instrumental in driving our understanding of disease, mainly because it reduces costs per sample, enables the detection of low frequency variants and allows for content customization. Manually designing targeted NGS panels is time- and resource- consuming, but QIAGEN’s primer design algorithms streamline and simplify the process, to deliver the highest possible design coverage. A case study on custom DNA glioma panels will be discussed for clinical research applications in order to molecular classify glioblastomas and the stem cells isolated in 4 molecular subclasses following validation in a clinical research setting to improve results in the molecular definition of gliomas according to WHO classification.
- How to approach customer panel design entering your own content, such as genes or genomic coordinates
- Elements required to overcome challenges of tumor profiling
- Validating a custom DNA panel from research to molecular definition of gliomas